HYUNDAI BIOSCIENCE Mediaroom - PR Newswire APAC

Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD

SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MO...

2024-09-18 09:26 1352

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease...

2024-09-11 14:25 1183

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patie...

2024-08-28 17:29 1252

ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients...

2024-07-11 14:07 1980

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-bor...

2024-06-26 09:17 1751

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience...

2024-04-25 21:41 1542

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

* The only solution for intractable cancer caused by mutations in the p53 gene * Planning clinica...

2024-04-25 17:11 1397

Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer

* Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients wi...

2024-04-22 17:51 1426

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bios...

2024-04-19 13:17 2338

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

SEOUL, South Korea, April 18, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bio...

2024-04-19 10:54 2326

Latest News

Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal

An oral antiviral drug from Korea may be a problem solver for COVID-19

CNPharm has succeeded in maintaining IC100 for 24 hours with one injection

Hyundai Bioscience leads in the repurposing of Niclosamide

Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem

Hyundai Bioscience: A Korean bio-tech solves the bioavailability issue of Niclosamide

'Curing Cancer without Surgery'